The UK government has confirmed that CE-marked medical devices and in vitro diagnostic devices (IVDs) will continue to be accepted in Great Britain on a long-term basis. The decision covers products ranging from insulin pumps and replacement joints to diagnostic tests and surgical equipment, preserving access for patients and the NHS.
The policy follows a public consultation held from 16 February to 10 April 2026, which drew more than 1,000 responses from patients, healthcare organisations, industry and other stakeholders.
Under the confirmed approach, manufacturers of devices already approved for the EU market will not need to pursue a separate UK approval route. The change is aimed at avoiding duplication for manufacturers and maintaining stable supply and patient access to medical technologies.
More than 90% of medical devices currently registered for use in Great Britain carry a CE mark, meaning they have been assessed and approved for the European market. Continued recognition of that approval will help maintain uninterrupted access to treatments and technologies used by patients and the NHS.
The UKCA marking route will continue to operate alongside CE recognition as the domestic approval pathway for devices placed on the market in Great Britain. Guidance on placing UKCA- or CE-marked products on the market remains available.
